One in 25,000 people worldwide is affected by neurofibromatosis type 2 (NF2), a condition where the loss of a tumour suppressor called Merlin results in multiple tumours in the brain and nervous system.
Jan 14, 2013
0
0
Researchers at McGill University have discovered that a key regulator of energy metabolism in cancer cells known as the AMP-activated protein kinase (AMPK) may play a crucial role in restricting cancer cell growth. AMPK acts ...
Dec 27, 2012
0
0
Cancer scientists led by Dr. John Dick at the Princess Margaret Cancer Centre have found a way to follow single tumour cells and observe their growth over time. By using special immune-deficient mice to propagate human colorectal ...
Dec 13, 2012
0
0
New research out of the United Kingdom is showing that a common drug used in the fight against breast cancer could also be employed in the fight against other tumours. The drug in question is geldanamycin, and has made a ...
Dec 5, 2012
0
0
A drug commonly used in treating breast cancer could have far wider benefits, offering a new way of preventing cancers spreading through the body, according to a University of Leeds-led study.
Nov 6, 2012
0
0
(Medical Xpress)—A*STAR scientists have identified a biomarker of the most lethal form of brain tumours in adults − glioblastoma multiforme. The scientists found that by targeting this biomarker and depleting it with ...
Sep 4, 2012
0
0
Different genetic mistakes driving skin cancer may affect how patients respond to the drug vemurafenib, providing grounds to screen people with melanoma skin cancer before treatment, a new study by Cancer Research UK scientists ...
Aug 14, 2012
0
0
The cancer drug bevacizumab (Avastin) offers only a modest benefit in delaying disease progression in patients with advanced stage breast cancer, according to a systematic review by Cochrane researchers. The researchers assessed ...
Jul 10, 2012
0
0
(Medical Xpress) -- Researchers at Imperial College London have discovered a molecule that plays an important role in driving prostate cancer growth, and could be a target for new therapies.
Jul 3, 2012
0
0
Mutations in a gene called KRAS are causally associated with acquired resistance to targeted therapies for colorectal cancers (CRC), according to new findings from EU-funded researchers from Italy and their research colleagues ...
Jun 25, 2012
0
0
